Kim Lien Randall Huber

Dr. Kim Lien Randall Huber


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Ophthalmology Retina
Verified
Journal Article
Open access
HSHeiko Stino
Heiko Stino
KHKim Lien Randall Huber
Kim Lien Randall Huber
MNMichael Niederleithner
Michael Niederleithner
NMNikolaus Mahnert
Nikolaus Mahnert
ASAleksandra Sedova
Aleksandra Sedova
APAndreas Pollreisz
Andreas Pollreisz
To evaluate the association of microvascular lesions on ultra-widefield (UWF) color-fundus (CF) images with retinal nonperfusion (RNP) up to the midperiphery on single-capture widefield (WF) optical coherence tomography angiography (OCTA) in patients with diabetic retinopathy (DR). Cross-sectional study. Seventy-five eyes of 50 patients with mild to severe non-proliferative DR (NPDR) and proliferative DR (PDR) were included in this analysis. DR stage (Early Treatment Diabetic Retinopathy Study; ETDRS) and presence of predominantly peripheral lesions (PPL) were assessed on UWF-CF images acquired with a Zeiss Clarus 700. Single-capture 65°-WF-OCTA was performed using a PlexElite prototype (Carl Zeiss Meditec Inc.). A custom grid consisting of a central ETDRS grid extended by two rings reaching up to the midperiphery was overlaid to subdivide retinal areas visible on WF-OCTA en-face images. RNP was measured in each area and in total. Nonperfusion index (NPI) was calculated from total RNP. On UWF-CF images the number of microaneurysms, hemorrhages, neovascularizations, and areas with intraretinal microvascular abnormalities (IRMAs) were evaluated using the same grid. Association of diabetic lesions with RNP was calculated using Spearman correlations (rs). Median RNP on WF-OCTA was 0mm2 (0-0.9), 4.9mm2 (1.9-5.4), 23.4mm2 (17.8-37), and 68.4mm2 (40.8-91.7) in mild, moderate, severe NPDR and PDR, respectively. We found a statistically significant correlation (p<0.01) of overall RNP (rs=0.96,) and NPI (rs=0.97) on WF-OCTA with ETDRS level. Number of grid-fields affected by IRMAs on CF images was highly associated with NPI (rs=0.86, p<0.01). IRMAs and RNPs had similar topographic distributions with high correlations in affected areas. Eyes with PPL (n=43 eyes, 57%) on CF-images had a significantly higher NPI (p=0.014) than eyes without PPL. The combination of UWF-CF imaging and single-capture WF-OCTA allows precise and non-invasive analysis of the retinal vasculature up to the midperiphery in patients with DR. The presence and extent of IRMAs on CF images may serve as an indicator for underlying RNP, which is more pronounced in eyes with PPL.

21 December 2023 in Acta Ophthalmologica
Verified
Journal Article
Open access
KHKim Lien Randall Huber
Kim Lien Randall Huber
HSHeiko Stino
Heiko Stino
TSThomas Schlegl
Thomas Schlegl
ISIrene Steiner
Irene Steiner
GNGergely Nagy
Gergely Nagy
APAndreas Pollreisz
Andreas Pollreisz
Purpose: To compare detection rates of microaneurysms (MAs) on high‐speed megahertz optical coherence tomography angiography (MHz‐OCTA), fluorescein angiography (FA) and colour fundus photography (CF) in patients with diabetic retinopathy (DR).Methods: For this exploratory cross‐sectional study, MHz‐OCTA data were acquired with a swept‐source OCT prototype (A‐scan rate: 1.7 MHz), and FA and CF imaging was performed using Optos® California. MA count was manually evaluated on en face MHz‐OCTA/FA/CF images within an extended ETDRS grid. Detectability of MAs visible on FA images was evaluated on corresponding MHz‐OCTA and CF images. MA distribution and leakage were correlated with detectability on OCTA and CF imaging.Results: 47 eyes with severe DR (n = 12) and proliferative DR (n = 35) were included. MHz‐OCTA and CF imaging detected on average 56% and 36% of MAs, respectively. MHz‐OCTA detection rate was significantly higher than CF (p < 0.01). The combination of MHz‐OCTA and CF leads to an increased detection rate of 70%. There was no statistically significant association between leakage and MA detectability on OCTA (p = 0.13). For CF, the odds of detecting leaking MAs were significantly lower than non‐leaking MAs (p = 0.012). Using MHz‐OCTA, detection of MAs outside the ETDRS grid was less likely than MAs located within the ETDRS grid (outer ring, p < 0.01; inner ring, p = 0.028). No statistically significant difference between rings was observed for CF measurements.Conclusions: More MAs were detected on MHz‐OCTA than on CF imaging. Detection rate was lower for MAs located outside the macular region with MHz‐OCTA and for leaking MAs with CF imaging. Combining both non‐invasive modalities can improve MA detection.

16 September 2019 in Fertility & Reproduction
Verified
Journal Article
Open access
PDF file
FEFiona Eidenberger
Fiona Eidenberger
KHKim Lien Randall Huber
Kim Lien Randall Huber
PFPatricia Fuchs
Patricia Fuchs
NSNikola Simkovicova
Nikola Simkovicova
MIMartin Imhof
Martin Imhof
Background: An elevated DNA Fragmentation Index (DFI) has been associated with male infertility; therefore measuring the sperm nuclear DNA integrity appears to be useful in predicting the ability of spermatozoa to fertilize oocytes. Aim: To evaluate the effect of micronutrient supplementation over DFI values in subfertile men. Methods: This was a retrospective/comparative study that included a total of 306 subfertile males consulting the clinic from March 2011 to November 2017, who had performed the Sperm Chromatin Dispersion test (SCD) — a method used to detect DNA fragmentation — along with the initial semen analysis. Of the included population, n= 146 had received two daily oral capsules of a standardized combined micronutrient compound (Profertil® , Lenus Pharma, Vienna, Austria) for three months plus lifestyle change (study group). Each capsule contains L-carnitine, L-arginine, coenzyme Q10, zinc, vitamin E, folic acid, glutathione and selenium. Those who did not receive the active treatment (n= 160) but only engaged with lifestyle changes were considered controls. The SCD test was performed in both groups at baseline and after 3 months. Results: For the first statistical analysis, patients with an initial mean DFI of >15% were considered (n= 66 [37 were study and 29 were controls]). After 3 months, both groups displayed a significant decrease of mean DFI values. However, this decrease was more evident in the study group as compared to controls (10.54% vs. 14.48%, α= 0.05; p= 0.013). For the second statistical approach the entire population was considered (n= 306). After 3 months, only the study group displayed a significant decrease of the mean initial DFI value (10.16% to 6.49%, p < 0.0001); decrease that was more evident as compared to controls (6.49% vs. 8.82%, α= 0.05; p= 0.000020). Conclusions: Among subfertile men with a DFI >15%, both regimes significantly decreased sperm DNA fragmentation; however, when any baseline DFI value was considered, only treatment with the active standardized micronutrient compound achieved a significant better result.

15 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PWPaul Widmann-Sedlnitzky
Paul Widmann-Sedlnitzky
KHKim Lien Randall Huber
Kim Lien Randall Huber
ISIrene Steiner
Irene Steiner
MGMarkus Gumpinger
Markus Gumpinger
HSHeiko Stino
Heiko Stino
APAndreas Pollreisz
Andreas Pollreisz
Background/Objectives: Diabetic macular edema is caused by disruptions in the blood–retinal barrier, resulting in leakage and inflammation, appearing in optical coherence tomography as retinal fluid, hard exudates, and hyper-reflective foci. This study aimed to assess volumetric changes in hyper-reflective foci and hard exudates in faricimab-treated diabetic macular edema in real-world practice. Methods: This retrospective longitudinal study included forty-four eyes with faricimab-treated diabetic macular edema and follow-up of ≥40 weeks. Optical coherence tomography scans were analyzed at baseline, post-loading, 6 months and 1 year. Hyper-reflective foci and hard exudates were quantified across macular subfields using a machine-learning algorithm with manual correction. Outcomes included volumetric changes, best-corrected visual acuity, and central subfield thickness. Early morphologic responders were defined post-loading by ≥20% central subfield thickness reduction and/or central subfield thickness below 280 µm. Results: At 1 year, hyper-reflective foci and hard exudate volumes significantly decreased in the central subfield (median differences: −0.025 nL, p = 0.00028; −0.119 nL, p = 0.00025) and outer ring (−0.178 nL, p = 0.00041; −0.612 nL, p = 0.014). Hard exudate volume significantly decreased in the inner ring (−0.740 nL, p < 0.0001). Best-corrected visual acuity and central subfield thickness improved significantly (−0.10 logarithm of the minimum angle of resolution (logMAR), p = 0.0018; −48 µm, p < 0.0001). Total hyper-reflective foci volumes were similar between responders and non-responders. In contrast, hard exudate burden remained numerically higher in non-responders. Conclusions: During the year following the switch to faricimab, HRF and HE burden decreased alongside visual and anatomical improvement. HRF volumes were descriptively similar between early CST responders and non-responders, whereas HE burden remained numerically higher in non-responders.

Verified
Journal Article
Open access
PDF file
PWPaul Widmann-Sedlnitzky
Paul Widmann-Sedlnitzky
KHKim Lien Randall Huber
Kim Lien Randall Huber
ISIrene Steiner
Irene Steiner
HSHeiko Stino
Heiko Stino
LKLaura Kunze
Laura Kunze
APAndreas Pollreisz
Andreas Pollreisz
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.